Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q3 EPS of ($0.64), $0.16 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $14.24 million.

As of September 30, 2018, Aquestive's cash and cash equivalents were $64.0 million, as compared to $17.4 million as of December 31, 2017. In July 2018, Aquestive received net proceeds from its IPO of $63.5 million.

For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.